All In Biotech

Drug Trial Radar · NCT01533207

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Last checked: Nov 20, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

38

Actual

Start

Jun 4, 2012

Primary completion

Jun 30, 2018

Study completion Feb 9, 2019

Sponsor

Lead sponsor
Gynecologic Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Feb 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.

Conditions

  • Stage I Uterine Sarcoma AJCC v7
  • Uterine Corpus Leiomyosarcoma

Interventions

  • Clinical ObservationOther

    Patients followed clinically

  • DocetaxelDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • FilgrastimBiological

    Given subcutaneously (SC)

  • Gemcitabine HydrochlorideDrug

    Given IV

  • PegfilgrastimBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced DeathTime frame: Follow-up every 4 months for 3 years, then every 6 months for 2 years.

Locations

623 sites in 8 countries. Site status is shown where the registry gives one.

  • Tennessee Valley Gynecologic Oncology

    Huntsville, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Sutter Davis Hospital

    Davis, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Kaiser Permanente-Redwood City

    Redwood City, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Kaiser Permanente - Sacramento

    Sacramento, California

Showing 40 of 623 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.